449 related articles for article (PubMed ID: 33930048)
21. Comparative effectiveness of abatacept versus TNF inhibitors in rheumatoid arthritis patients who are ACPA and shared epitope positive.
Harrold LR; Wittstock K; Kelly S; Han X; Zhuo J; Schrader A; Middaugh N; Moore PC; Khaychuk V
Adv Rheumatol; 2024 Jan; 64(1):10. PubMed ID: 38243281
[TBL] [Abstract][Full Text] [Related]
22. The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries.
Courvoisier DS; Chatzidionysiou K; Mongin D; Lauper K; Mariette X; Morel J; Gottenberg JE; Bergstra SA; Suarez MP; Codreanu C; Kvien TK; Santos MJ; Pavelka K; Hetland ML; Askling J; Turesson C; Kubo S; Tanaka Y; Iannone F; Choquette D; Nordström DC; Rotar Z; Lukina G; Gabay C; Van Vollenhoven R; Finckh A
Rheumatology (Oxford); 2021 Feb; 60(2):820-828. PubMed ID: 32810263
[TBL] [Abstract][Full Text] [Related]
23. Leukocytapheresis for rheumatoid arthritis cases that are super-resistant to any class of biological drugs and tofacitinib.
Mori S
Transfus Apher Sci; 2020 Dec; 59(6):102920. PubMed ID: 32896492
[TBL] [Abstract][Full Text] [Related]
24. Comparison of infection-related hospitalization risk and costs in tumor necrosis factor inhibitor-experienced patients with rheumatoid arthritis (RA) treated with abatacept or other targeted disease-modifying anti-rheumatic drugs (tDMARDs).
Paul D; Patil D; McDonald L; Patel V; Lobo F
J Med Econ; 2020 Sep; 23(9):1025-1031. PubMed ID: 32427547
[No Abstract] [Full Text] [Related]
25. Association of first, second, and third-line bDMARDs and tsDMARD with drug survival among seropositive rheumatoid arthritis patients: Cohort study in A real world setting.
Choi S; Ghang B; Jeong S; Choi D; Lee JS; Park SM; Lee EY
Semin Arthritis Rheum; 2021 Aug; 51(4):685-691. PubMed ID: 34139521
[TBL] [Abstract][Full Text] [Related]
26. A comparison of discontinuation rates of tofacitinib and biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis: a systematic review and Bayesian network meta-analysis.
Park SK; Lee MY; Jang EJ; Kim HL; Ha DM; Lee EK
Clin Exp Rheumatol; 2017; 35(4):689-699. PubMed ID: 28079510
[TBL] [Abstract][Full Text] [Related]
27. Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world study.
Simon TA; Boers M; Hochberg M; Baker N; Skovron ML; Ray N; Singhal S; Suissa S; Gomez-Caminero A
Arthritis Res Ther; 2019 Nov; 21(1):228. PubMed ID: 31703717
[TBL] [Abstract][Full Text] [Related]
28. Associations between an expanded autoantibody profile and treatment responses to biologic therapies in patients with rheumatoid arthritis.
Petro AD; Dougherty J; England BR; Sayles H; Duryee MJ; Hunter CD; Kremer JM; Pappas DA; Robinson WH; Curtis JR; Thiele GM; Mikuls TR
Int Immunopharmacol; 2021 Feb; 91():107260. PubMed ID: 33360371
[TBL] [Abstract][Full Text] [Related]
29. Patterns of biologic and targeted-synthetic disease-modifying antirheumatic drug use in rheumatoid arthritis in Australia.
Fletcher A; Lassere M; March L; Hill C; Barrett C; Carroll G; Buchbinder R
Rheumatology (Oxford); 2022 Oct; 61(10):3939-3951. PubMed ID: 35094044
[TBL] [Abstract][Full Text] [Related]
30. Comparative Risk of Alzheimer Disease and Related Dementia Among Medicare Beneficiaries With Rheumatoid Arthritis Treated With Targeted Disease-Modifying Antirheumatic Agents.
Desai RJ; Varma VR; Gerhard T; Segal J; Mahesri M; Chin K; Horton DB; Kim SC; Schneeweiss S; Thambisetty M
JAMA Netw Open; 2022 Apr; 5(4):e226567. PubMed ID: 35394510
[TBL] [Abstract][Full Text] [Related]
31. Comparative effectiveness of TNF inhibitors and tocilizumab with and without conventional synthetic disease-modifying antirheumatic drugs in a pan-European observational cohort of bio-naïve patients with rheumatoid arthritis.
Lauper K; Mongin D; Iannone F; Kristianslund EK; Kvien TK; Nordström DC; Pavelka K; Pombo-Suarez M; Rotar Z; Santos MJ; Codreanu C; Lukina G; Gale SL; John M; Luder Y; Courvoisier DS; Gabay C
Semin Arthritis Rheum; 2020 Feb; 50(1):17-24. PubMed ID: 31280937
[TBL] [Abstract][Full Text] [Related]
32. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.
Wadström H; Frisell T; Askling J;
JAMA Intern Med; 2017 Nov; 177(11):1605-1612. PubMed ID: 28975211
[TBL] [Abstract][Full Text] [Related]
33. Retention Rate and Safety of Biologic and Targeted Synthetic DMARDs in Patients with RA-Associated Interstitial Lung Disease: A KOBIO Registry Study.
Lee SK; Shin K; Jung JY; Suh CH; Kim JW; Kim HA
BioDrugs; 2023 Mar; 37(2):247-257. PubMed ID: 36757601
[TBL] [Abstract][Full Text] [Related]
34. Effect of biologics and targeted synthetic disease-modifying anti-rheumatic drugs on fatigue in rheumatoid arthritis.
Choy EH
Rheumatology (Oxford); 2019 Nov; 58(Suppl 5):v51-v55. PubMed ID: 31682274
[TBL] [Abstract][Full Text] [Related]
35. Short- and longer-term cancer risks with biologic and targeted synthetic disease-modifying antirheumatic drugs as used against rheumatoid arthritis in clinical practice.
Huss V; Bower H; Wadström H; Frisell T; Askling J;
Rheumatology (Oxford); 2022 May; 61(5):1810-1818. PubMed ID: 34324640
[TBL] [Abstract][Full Text] [Related]
36. Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study.
Ozen G; Pedro S; Schumacher R; Simon TA; Michaud K
Arthritis Res Ther; 2019 Jun; 21(1):141. PubMed ID: 31174592
[TBL] [Abstract][Full Text] [Related]
37. Drug retention of biological DMARD in rheumatoid arthritis patients: the role of baseline characteristics and disease evolution.
Lauper K; Mongin D; Alpizar-Rodriguez D; Codreanu C; Iannone F; Kristianslund EK; Kvien TK; Pavelka K; Pombo-Suarez M; Santos MJ; Gabay C; Finckh A; Courvoisier DS
Rheumatology (Oxford); 2019 Dec; 58(12):2221-2229. PubMed ID: 31209481
[TBL] [Abstract][Full Text] [Related]
38. Cost per response for abatacept versus adalimumab in rheumatoid arthritis by ACPA subgroups in Germany, Italy, Spain, US and Canada.
Weijers L; Baerwald C; Mennini FS; Rodríguez-Heredia JM; Bergman MJ; Choquette D; Herrmann KH; Attinà G; Nappi C; Merino SJ; Patel C; Mtibaa M; Foo J
Rheumatol Int; 2017 Jul; 37(7):1111-1123. PubMed ID: 28560470
[TBL] [Abstract][Full Text] [Related]
39. Clinical Implications of Shared Epitope and Anti-citrullinated Peptide Antibody in Patients With Rheumatoid Arthritis.
Jung SM; Park YJ; Park KS; Kim KJ
J Rheum Dis; 2022 Jul; 29(3):171-180. PubMed ID: 37475973
[TBL] [Abstract][Full Text] [Related]
40. Real-world evaluation of effectiveness, persistence, and usage patterns of tofacitinib in treatment of rheumatoid arthritis in Australia.
Bird P; Littlejohn G; Butcher B; Smith T; da Fonseca Pereira C; Witcombe D; Griffiths H
Clin Rheumatol; 2020 Sep; 39(9):2545-2551. PubMed ID: 32157469
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
